Among the many different types of cancers, acute myeloid leukemia is one of the most serious. This type of cancer is characterized by abnormal cells that form in the bone marrow. The disease can also be characterized by relapses after treatment.
Symptoms
Symptoms of acute myeloid leukemia are a result of changes in the body’s blood count. The disease may begin in the bone marrow or other blood-forming organs and can progress rapidly. Without treatment, the disease may spread to other organs, such as the spleen and testicles.
The disease is caused by genetic changes in the blood stem cells in the bone marrow, which interferes with normal bone marrow function. These cells then produce abnormal white blood cells or platelets. Symptoms include fatigue, bruising, pain in the joints, and bleeding. A low blood count also makes the body more susceptible to infections.
Leukemia may also spread to other parts of the body, such as the lymph nodes, spleen, and liver. It can also cause bleeding in the brain or joints. This can result in clotting problems and an embolism. Affected patients also experience pain in the joints, and may have blurred vision or neck stiffness.
Acute myeloid leukemia is a disease that is usually found in adults. Cancer begins in the bone marrow and affects the lymphatic and blood systems. The cells become immature and lack the infection-fighting properties of normal blood cells. The abnormal cells also crowd out the normal bone marrow cells.
Diagnosis
Usually, the first step in diagnosing acute myeloid leukemia is a blood test. This test measures the number of white blood cells and other substances in your blood. A pathologist will then look at your blood under a microscope. If your blood has a low number of white blood cells, it is a sign of leukemia.
If your blood test shows that you have a low number of white blood cells, the next step is to take a sample of your bone marrow. The bone marrow is a fatty, spongy tissue that is located inside larger bones. A pathologist will then look at the marrow to see if there are any abnormal cells.
Sometimes, imaging tests are also done to determine if your leukemia has spread. These tests may involve computed tomography (CT) and magnetic resonance imaging (MRI). If your doctor thinks that your leukemia has spread, a lumbar puncture may be done.
A lumbar puncture is a procedure that involves a needle being inserted into the lower part of your spine. The lumbar puncture may be done for a variety of reasons, including if your leukemia is spreading to your nervous system. This procedure will also be used to test your cerebrospinal fluid for cancer cells.
Treatment options
Choosing a treatment plan for acute myeloid leukemia depends on the type of leukemia and the patient’s age and general health. Treatments may include chemotherapy, radiation therapy, or a stem cell transplant. It’s important to discuss your treatment options with your doctor so you can make an informed decision.
Traditionally, the remission induction phase included intensive chemotherapy. However, newer treatment options have changed the way chemotherapy is used. Some patients are hospitalized, while others can recuperate at home between courses.
Chemotherapy is given in a specialist center and may include two or three drugs. Patients also may be given antibiotics to prevent infections. They may also be required to receive transfusions for several weeks.
After the treatment is finished, patients may be put on a maintenance schedule of chemotherapy. This phase may include a lower-strength medication, or it may include chemotherapy for a longer period of time. The goal of the maintenance treatment is to achieve complete remission.
Some patients may be able to have an autologous bone marrow transplant, where healthy stem cells are removed from the patient and re-infused. Others may be referred to a clinical trial. Some patients may benefit from allogeneic stem cell transplantation, where healthy stem cells are derived from a donor.
Relapses after treatment
During the past years, acute myeloid leukemia has benefited from improved therapy and understanding of its pathogenesis. Despite these developments, relapses of AML are a common phenomenon. Typically, relapses are within the first two years of diagnosis. The treatment options for relapses include chemotherapy and salvage therapy.
AML is fast-growing cancer that can develop relapses after treatment. It has a high recurrence rate and a poor prognosis. It is characterized by the re-appearance of blasts in the bone marrow. Relapses can occur months or years after treatment.
The best treatment options for acute myeloid leukemia relapses include allogeneic hematopoietic stem cell transplantation (HSCT) and chemotherapy. However, not all patients are eligible for allogeneic HSCT. A clinical evaluation should determine whether the patient is a good candidate for transplantation.
Relapses after treatment for acute myeloid leukemia have been reported in a variety of patient subgroups, and a number of factors are known to contribute to the outcome. For instance, a favorable karyotype is associated with a high response rate. Other factors include age less than 30 years, long CR1, and a 5-year DFS.
AMG 330 is an anti-CD33 BiTE(r) antibody that is being tested in clinical trials. Several other targeted therapy options are being investigated in the clinical setting.
Colony-stimulating factors
Various colony-stimulating factors (CSFs) have been investigated as hematopoietic growth factors. These factors may be useful in the treatment of AML. They may help accelerate the recovery of granulocytes following chemotherapy. In addition, they may also promote the cytotoxicity of chemotherapy.
Colony-stimulating factors play a central role in leukocyte function. They are secreted glycoproteins that bind to receptor proteins on hematopoietic stem cells. They affect the production, differentiation, and function of leukemic and related white blood cells. They also contribute to the survival and proliferation of macrophages. They are also targeted in various inflammatory disorders.
In addition to their role as hematopoietic growth factors, colony-stimulating factors are known to stimulate bone marrow stem cells. They also stimulate osteoclast precursors. GM-CSF has been used for the priming of leukemic cells and for the acceleration of hematopoietic recovery.
Several studies have evaluated the use of GM-CSF in the treatment of AML. The results have shown that it has a beneficial effect on disease-free survival. However, these studies were conducted in young and middle-aged patients with previously untreated AML. GM-CSF has not been shown to affect osteoclastic bone resorption in murine marrow cultures. However, the combination of G-CSF with chemotherapy is still controversial.
TP53 mutations
TP53 mutations in acute myeloid leukemia (AML) are associated with a dismal prognosis. The TP53 gene encodes p53, a tumor suppressor. It is activated by a number of stress signals, including hypoxia, nutrient deprivation, and oncogene activation. It is a crucial component of the DNA damage response. A TP53 mutation increases the rate of cytogenetic aberrations. It also may determine decreased response to treatments.
TP53 mutations are often associated with a complex karyotype. In AML and MDS, the TP53 gene is located on chromosome 17p13.1. The mutations are missense mutations in the DNA binding domain of the gene. TP53 aberrations are most common in de novo AML.
The TP53 clone size in AML patients is similar to that in MDS. The size of the clone exceeds the number of bone marrow blast cells. However, the size of the clone does not correlate with overall survival. In this study, TP53-mutated clones expanded slightly during the course of transformation to secondary AML.
The incidence of TP53 mutations in AML is not as high as in MDS. There are a number of studies that suggest that MDS and AML may be artificially segregated. In this study, TP53 mutations were detected in a subgroup of MDS patients.
Thrombocytopenia
Thrombocytopenia is a common complication of acute myeloid leukemia. The underlying mechanism is not entirely understood. However, studies have shown that abnormalities of megakaryocytes may contribute to the development of thrombocytopenia. These cells are the cell of origin for mature platelets. They have been shown to undergo an aggressive growth process, which results in reductions in their number.
In this study, we investigated the effect of a single injection of recombinant human thrombopoietin (rhTPO) on platelet counts in patients with chemotherapy-induced thrombocytopenia. Patients were divided into two groups according to the medications they were administered. Those who received rhTPO showed an increase in platelet counts after a single injection.
Thrombocytopenia has been reported to occur after chemotherapy for acute myeloid leukemia (AML). However, the relationship between peripheral blood platelet counts and survival in AML is unknown. The current prevailing hypothesis is that AML spatially displaces nonleukemic hematopoiesis from the bone marrow. A possible explanation is that excessive apoptosis of megakaryocytes leads to a decrease in their production of platelets.
Thrombocytopenia in patients with AML is associated with abnormalities of megakaryocytes. These cells have an aberrant distribution of cytoplasmic organelles, such as the DMS and OCS, which drive the formation of mature platelets. In AML, megakaryocytes display undifferentiated features, such as an asymmetric nucleus, and aberrant distribution of cytoplasmic organelles. A larger study is needed to better understand the significance of these features.
Health Sources:
Health A to Z. (n.d.). HSE.ie. https://www2.hse.ie/az/
Directory Health Topics. (n.d.). https://www.healthline.com/directory/topics
Health A-Z. (2022, April 26). Verywell Health. https://www.verywellhealth.com/health-a-z-4014770
Harvard Health. (2015, November 17). Health A to Z. https://www.health.harvard.edu/health-a-to-z
Health Conditions A-Z Sitemap. (n.d.). EverydayHealth.com. https://www.everydayhealth.com/conditions/
